Skip to content
akaturk Academic measurement
Sign in Register

Academician

İLHAN HACIBEKİROĞLU

PROFESÖR

SAKARYA ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ

  • Ana Dal Sağlık Bilimleri Temel Alanı
  • Yan Dal Tıbbi Onkoloji (İç Hastalıkları)

A quick look at recorded outputs — details below.

  • Articles 57
  • Projects 0
  • Books 0
  • Proceedings 0
  • Patents 0
  • Artistic 0
Scopus (SJR) Q1 20 Q2 15 Q3 15 Q4 5
WoS (JCR) Q1 9 Q2 14 Q3 17 Q4 12
TR Index 4 articles

Field+year+type normalized OpenAlex percentiles — not Clarivate ESI / SciVal.

Top 1% articles 0
Top 10% articles 7
Avg percentile 66.2%
Top 1% share 0.0%
Top 10% share 12.7%

Articles

Articles with YÖKSİS and OpenAlex source split; narrow by quartile or TR Index.

Index filters

57 publications total

Scopus (SJR)
Q1 20 Q2 15 Q3 15 Q4 5
WoS (JCR)
Q1 9 Q2 14 Q3 17 Q4 12
TR Index
4 articles

Article list

  1. 2026 Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study Cancers DOI 10.3390/cancers18121979 YÖKSİS SJR Q1 JCR Q2 OpenAlex 62.6%
  2. 2026 Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy Cancers DOI 10.3390/cancers18142302 YÖKSİS SJR Q1 JCR Q2 OpenAlex 70.8%
  3. 2026 Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group Journal of Clinical Medicine DOI 10.3390/jcm15135224 YÖKSİS SJR Q2 JCR Q1 OpenAlex 61.7%
  4. 2025 Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first‐line therapy in advanced nonuterine leiomyosarcoma: A multicenter real‐world study International Journal of Cancer DOI 10.1002/ijc.70212 YÖKSİS SJR Q1 JCR Q2 OpenAlex 35.0%
  5. 2025 Real-world comparison of doxorubicin-ifosfamide versus gemcitabine-docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study DISCOVER ONCOLOGY DOI 10.1007/s12672-025-03886-1 YÖKSİS SJR Q2 JCR Q3 OpenAlex 80.6%
  6. 2025 CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC JTO Clinical and Research Reports DOI 10.1016/j.jtocrr.2025.100859 YÖKSİS SJR Q1 JCR Q2 OpenAlex 86.6%
  7. 2025 Gustave Roussy immune score as an independent prognostic factor for treatment response and survival in advanced renal cell carcinoma treated with nivolumab in second-line and beyond Frontiers in Oncology DOI 10.3389/fonc.2025.1657053 YÖKSİS SJR Q2 JCR Q3 OpenAlex 88.3%
  8. 2025 Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study Scientific Reports DOI 10.1038/s41598-024-80587-9 YÖKSİS SJR Q1 JCR Q1
  9. 2025 Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group International Journal of Cancer DOI 10.1002/ijc.70213 YÖKSİS SJR Q1 JCR Q2 OpenAlex 68.1%
  10. 2025 Induction or Adjuvant Chemotherapy in Patients with Locally Advanced Nasopharyngeal Cancer Receiving Chemoradiotherapy? A Turkish Oncology Group Study Journal of Clinical Medicine DOI 10.3390/jcm14124189 YÖKSİS SJR Q2 JCR Q1 OpenAlex 14.7%
  11. 2025 Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning Approach Cancers DOI 10.3390/cancers17020233 YÖKSİS SJR Q1 JCR Q2 OpenAlex 76.7%
  12. 2025 Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study Clinical Breast Cancer DOI 10.1016/j.clbc.2025.03.003 YÖKSİS SJR Q2 JCR Q3 OpenAlex 88.9%
  13. 2025 HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy Turkish Journal of Clinics and Laboratory DOI 10.18663/tjcl.1639022 YÖKSİS TR Index OpenAlex 69.4%
  14. 2024 Total Neoadjuvant Therapy Versus Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Real-World Study Cancers DOI 10.3390/cancers16183213 YÖKSİS SJR Q1 JCR Q2 OpenAlex 85.9%
  15. 2024 Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases Scientific Reports DOI 10.1038/s41598-024-56046-w YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 95.1%
  16. 2024 A propensity score‐matched comparison of neoadjuvant chemoradiotherapy with cisplatin‐5FU and carboplatin–paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study Cancer Medicine DOI 10.1002/cam4.70002 YÖKSİS SJR Q1 JCR Q2 OpenAlex 62.3%
  17. 2024 Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey Journal of Chemotherapy DOI 10.1080/1120009X.2024.2430845 YÖKSİS SJR Q3 JCR Q3 OpenAlex 62.3%
  18. 2024 The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing Journal of Chemotherapy DOI 10.1080/1120009X.2024.2305066 YÖKSİS SJR Q3 JCR Q3 OpenAlex 58.4%
  19. 2024 Clinicopathologic Analysis and Prognostic Factors for Survival in Patients with Operable Ampullary Carcinoma: A Multi-Institutional Retrospective Experience Medicina DOI 10.3390/medicina60050818 YÖKSİS SJR Q2 JCR Q1 OpenAlex 59.3%
  20. 2024 Efficacy of Neoadjuvant Chemotherapy in Lobular and Rare Subtypes of Breast Cancer J Coll Physicians Surg Pak DOI 10.29271/jcpsp.2024.01.37 YÖKSİS SJR Q3 JCR Q3 OpenAlex 65.1%

Back to academicians